113 results about "Retinoic acid" patented technology

A composition, and uses and methods of using the composition, said composition comprising: (a) at least 0.1 wt. % of a retinoid component selected from retinol, retinal, retinoic acid or combinations thereof; (b) one or more water-soluble antioxidant; (c) one or more oil-soluble antioxidant; (d) from 0.1 to 3 wt. % of a thickener component comprising polyacrylic acid, polyacrylate, polyacrylamide, polysaccharide or combinations thereof; and (e) from 4 to 20 wt. % of an emollient component comprising a benzoic acid ester, a silicone oil, a triglyceride or a combination thereof.

The invention provides retinyl sodium hyaluronate and a composition thereof, which are applied to the fields of cosmetics and medicines. The retinoyl sodium hyaluronate is characterized in that all-trans retinoic acid and 13-cis-retinoic acid are esterified with sodium hyaluronate according to a molar ratio of (1.5-3.0): 1, and the esterification degree is 1%-12%; the composition disclosed by the invention is characterized by comprising retinyl sodium hyaluronate and a polyhydric alcohol compound in a mass ratio of 1: (1-10). The sodium retinoyl hyaluronate has a remarkable effect of preventing and treating acne, and the composition is beneficial to improving the stability of the sodium retinoyl hyaluronate and prolonging the validity period of a raw material product of the sodium retinoyl hyaluronate. The retinyl sodium hyaluronate and the composition thereof can be used for preparing cosmetics and medical products for whitening, resisting aging, controlling oil and removing acnes.

The invention discloses a composition with moisturizing and anti-aging effects and application of the composition in cosmetics, the moisturizing and anti-aging composition comprises retinyl sodium hyaluronate and a radix semiaquilegiae extract, and tests prove that the retinyl sodium hyaluronate and the radix semiaquilegiae extract have a synergistic effect, so that the moisturizing and anti-aging effects are achieved. The compound has a remarkable effect of promoting expression of an X VII type collagen gene and generation of AQP3 protein (aquaporin 3), can be used in cosmetics to improve the problems of dry skin and aging, and is good in stability, safe and non-irritant.

The invention relates to application of a retinoic acid compound in preparation of a medicine for treating and / or preventing glioblastoma. Compared with the prior art, the retinoic acid compound (1uM, 5uM) group has the advantages that the tumor inhibition rate of a glioblastoma organ is higher than that of an apatinib (1uM, 5uM) group, and is higher than that of an apatinib (1uM, 5uM) group. The subcutaneous tumor inhibition rate of glioblastoma cells of a retinoic acid compound (0.5 mg / kg and 5mg / kg) group is higher than that of an apatinib (32.5 mg / kg) group, and is higher than that of the apatinib (32.5 mg / kg) group in tumor pathological blood vessel inhibition rate. Therefore, the medicine (retinoic acid compound) for treating and (or) preventing the glioblastoma has a remarkable treatment and (or) preventing effect on the glioblastoma.

The invention discloses a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T and application of the sequential anti-tumor strategy, belongs to the technical field of biological medicine, and particularly relates to a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T. According to the strategy, tumor fibrosis and an acidic microenvironment are improved at the same time by applying a tumor-associated fibroblast (CAF) targeted drug and a proton pump inhibitor, and then sequential injection of CAR T is performed for combined treatment of solid tumors. Wherein the CAF targeting drug is selected from all-trans retinoic acid, calcipotriol, losartan and minetil, the proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy firstly destroys a compact physical barrier of a tumor microenvironment, improves acidity of a tumor site, ensures infiltration, survival and proliferation of CAR T at the tumor site, and then utilizes specificity of CAR T to inhibit growth of solid tumors in a targeted manner, especially triple negative breast cancer with a high malignancy degree.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

An in vitro method for constructing a human vaginal epithelial model, which uses two stages of submerged culture and air-liquid surface culture to form a multilayered in vitro 3D model. During the submerged culture process, a low concentration of Ca 2+ (0.7~1.5mM) prevents the differentiation of vaginal epithelial cells; vitamin D is added to ensure that there are enough epithelial cells to maintain cell differentiation in the subsequent gas-liquid culture stage. In the gas-liquid interface culture stage, all-trans retinoic acid and 17 β-estradiol are added to the differentiation medium, among which all-trans retinoic acid can inhibit the continuous keratinization of vaginal epithelial cells and prevent excessive keratinization to form a stratum corneum. 17 β-estradiol enhances the barrier function of the vaginal epithelial model. Therefore, the joint use of all-trans retinoic acid and 17 β-estradiol can ensure that the epithelial layer of the vaginal epithelial model cannot differentiate into a mature stratum corneum, but still has a certain barrier function.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and all-trans retinoic acid or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment of cancer.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human colon cancer cells (HCT116) are taken as target cells, and retinoic acid-induced protein expression of the target cells is reduced by adopting a gene knockout technology, so that host factors capable of effectively inhibiting CHIKV infection of the human colon cancer cells are found, and the purpose of blocking CHIKV infection from the source is achieved. It is found that retinoic acid induced protein 16 (RAI16) plays an important role in CHIKV infected HCT116 cells, and CHIKV infection can be obviously promoted by down-regulating expression of RAI16. The invention provides an application of RAI16 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The invention provides application of AhR in regulation and control of ALDH1A3 and synthesis of retinoic acid. Specifically, the invention provides an application of a reagent in preparation of a product, the reagent is used for regulating and controlling AhR or an AhR signal channel, and the product is used for at least one of the following: regulating and controlling ALDH1A3; regulating and controlling synthesis of retinoic acid; the expression of skin barrier function related genes is regulated and controlled. The inventor provides the application by utilizing the relationship between AhR and ALDH1A3, the relationship between ALDH1A3 and retinoic acid and the relationship between retinoic acid and the skin barrier function, and when an AhR or AhR signal channel is regulated and controlled, the generation of ALDH1A3, retinoic acid synthesis and skin barrier function gene transcription can be regulated and controlled at the same time.

The invention belongs to the technical field of veterinary vaccine adjuvants, and particularly relates to an intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion as well as a preparation method and application of the intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion. The intestinal tract targeted saccharum alhagi polysaccharide-aluminum adjuvant Pickering emulsion is AHPPE, the AHPPE is formed by mixing an oil phase and a water phase, and the volume ratio of the oil phase to the water phase is 1: (9-13); the oil phase is prepared from the following raw materials: squalene and retinoic acid; the mass ratio of the squalene to the retinoic acid is 1: (0.7-0.8); the water phase is prepared from the following raw materials: saccharum alhagi polysaccharide and aluminum hydroxide; the mass ratio of the saccharum alhagi polysaccharide to the aluminum hydroxide is 1: (10-13). According to the preparation method provided by the invention, the problems that retinoic acid is difficult to dissolve in water and the metabolism speed of saccharum alhagi polysaccharide is high are solved, and meanwhile, an organism can be induced to generate effective systemic immunity and intestinal mucosa immunity by injecting AHPPE.

The present application relates to the technical field of cosmetic raw materials, and provides tocopheryl retinoate and application thereof in cosmetics and / or skin care products. The tocopheryl retinoate introduces a tocopherol group with antioxidant activity into the molecular structure of retinoic acid, significantly improves the light stability and thermal stability of the compound while maintaining the biological activity of vitamin A ingredients, and effectively reduces the irritation to the skin. The tocopheryl retinoate is suitable for the cosmetic and / or skin care product system used in the daytime, can improve the skin condition, repair the skin barrier and protect the skin, and has good safety and wide application prospect.

The present invention provides a retinoic acid derivative that has high stability and water solubility. The present invention relates to a carboxylic acid ester compound of trehalose or a derivative thereof and retinoic acid.

The present invention relates to a conjugate compound comprising 13-cis-retinoic acid and vitamin C, and its pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The present compound has a much better water solubility than that of retinoic acid, and thus reduces an effective dosage of retinoic acid and minimizes side effect. The present compound increases the efficiency and concentration of 13-cis-retinoic acid to across the cell membrane into the cell. The present compound is useful in treating cancer such as pancreatic cancer.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

The present invention discloses the use of garlic extracellular vesicles in the preparation of a drug for treating acne. Fresh Yunnan purple-skinned garlic cloves are peeled, the rhizomes removed, and then washed and juiced. The squeezed garlic juice is subjected to ultracentrifugation. The resulting solution is subjected to sucrose gradient purification. The resulting solution is mixed and packaged to obtain garlic extracellular vesicles. The extracted garlic extracellular vesicles are applied to acne as an experimental acne treatment drug. Retinoic acid cream is used as a positive control group, and normal saline is used as a model group. The therapeutic effect of garlic extracellular vesicles on acne healing in rats is observed. The results show that garlic extracellular vesicles can effectively increase the reduction rate of acne thickness, significantly increase the reduction rate of acne area, significantly increase the smoothness and flatness of skin healing, and significantly shorten the acne healing period.

The invention discloses an application of an activator combined by one or more genes / proteins in preparation of drugs for treating hypertrophic scars, and belongs to the technical field of biological medicines. In order to solve the problem that when retinoic acid cream is used for preparing hypertrophic scars, a specific mode and an action target of a retinoic acid signal channel for regulating and controlling fibroblasts are not disclosed yet, the action target and a regulation and control mechanism of ATRA for regulating and controlling fibroblast activation and glucose metabolism remodeling are explored through in-vivo and in-vitro experiments; and on the basis of a Cre-loxP system, the function of the target gene is verified. Researches in the invention show that ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 by activating RAR alpha on one hand, and ATRA promotes transcription of HIC1 and inhibits transcription and expression of TGF-beta1 on the other hand; on the other hand, the transcription of PCK1 and PCK2 is promoted, so that the proliferation and abnormal activation of HSFs are reduced, and the occurrence and development processes of hypertrophic scars are finally inhibited. The conclusion provides a sufficient theoretical basis for inhibiting hypertrophic scar formation by ATRA.

The present invention provides an application of a reagent for detecting retinol metabolites in the preparation of a tool for diagnosing and / or treating pneumoconiosis, and relates to the field of biomedical technology. The present invention verifies that retinol metabolism disorders and all-trans retinoic acid deficiency are closely related to the occurrence of pneumoconiosis, and therefore proposes to use retinol and all-trans retinoic acid as biomarkers for screening pneumoconiosis and apply them to the preparation of related products for diagnosing pneumoconiosis; at the same time, all-trans retinoic acid intervention for pneumoconiosis can effectively slow down the progression of pneumoconiosis, and therefore proposes for the first time to use all-trans retinoic acid as a drug for treating pneumoconiosis.

The present application relates to a culture medium for the culture of intestinal organoids characterized in that it comprises neuregulin 1 (NRG1) and all-trans retinoic acid (atRA). It also relates to a method using this medium to culture intestinal organoids.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

This invention discloses a solvate of rememega-2 and its preparation method. The rememega-2 solvate (compound II) provided by this invention has a purity of up to 99.15% compared with the existing rememega-2 methyl tert-butyl ether solvate. The preparation method includes the following steps: adding crude rememega-2 to a binary solvent, heating to 45℃~75℃, adding an antisolvent, stirring, crystallizing, cooling and filtering, and drying under reduced pressure to obtain rememega-2 solvate (compound II). Then, placing rememega-2 solvate (compound II) in ethanol and stirring to obtain rememega-2 (compound I). This route is simple to operate, the process is stable, and it is easy to scale up. Moreover, the rememega-2 (compound I) prepared by this solvate (compound II) has a purity of up to 99.66%, which is higher than that of rememega-2 (compound I) prepared by the existing rememega-2 methyl tert-butyl ether solvate. It also has better fluidity, does not caking, is easy to transfer, and is convenient for later production.

Described herein is a method of treating cancer by administering an effective concentration of liposomes of all-transretinoic acid.

This invention discloses a method for synthesizing an intermediate of retinoic acid, relating to the field of pharmaceutical organic synthesis technology, comprising the following steps: S1, in the presence of a base, 2-amino-3-chloropyridine and 4-bromopiperidine undergo a nucleophilic substitution reaction in solvent A to prepare compound III; S2, in the presence of a catalyst and ammonia solution, compound III undergoes an amination reaction in solvent B to prepare compound II; S3, compound II is dissolved in solvent C, and sequentially undergoes CDI cyclization and hydrogen chloride solution salt formation to prepare compound I, namely 1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. This invention is low-cost, uses mild reaction conditions, has a simple synthesis process, high yield, and eliminates the need for expensive and potentially unsafe excipients, effectively improving reaction safety, being environmentally friendly, and suitable for industrial production.

A method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors are described. The composition has a retinoic acid precursor and a resorcinol to impede oxidation of the precursor in situ in the composition.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

This invention, entitled "A Method and Product for Pretreatment of Mesenchymal Stem Cells and Its Application in Stroke Drugs," belongs to the field of biotechnology. The technical problem to be solved is to improve the function and therapeutic effect of mesenchymal stem cells. The key technical solution is a method for pretreatment of mesenchymal stem cells, including: culturing cells using an activation medium, culturing cells using a directional medium, and culturing cells under hypoxic conditions using an adaptation medium; the activation medium contains complete medium, IFN-γ, TNF-α, and IL-1β; the directional medium contains complete medium, sodium valproate, 5-azacytidine, and all-trans retinoic acid; the adaptation medium is a complete medium containing basal medium and free of animal serum. The pretreatment method of this invention enhances the anti-inflammatory, neuroprotective, and angiogenic capabilities of mesenchymal stem cells, showing significant therapeutic effects on stroke, and since it does not use animal serum, it meets clinical requirements.

Disclosed are methods of accelerating development of new hair follicles in pluripotent stem cell-derived skin organoids. In particular, disclosed are methods of accelerating development of new hair follicles in skin organoids by adding one or more growth factors, such as FGF10, FGF20, BIO, ruxolitinib, tofacitinib, LDN193189, vitamin E, GDNF, retinoic acid, or IGF2. The growth factors are added to a culture of skin organoid at critical windows of time of the skin organoid development, such as after (or upon) the formation of epidermis and dermis in the skin organoid.

The present invention relates to a composition for preventing or treating autoimmune diseases. In particular the present invention relates to a composition that prevents or treats the disease by specifically targeting the immune cells responsible for the autoimmune reaction. Thus one aspect relates to a composition comprising DDA and TDB or MMG, retinoic acid or analogues thereof, and at least one autoimmune antigen for use in prevention or treatment of autoimmune diseases.

The invention provides an experimental method for verifying the curative effect of retinoic acid on schizophrenia, which comprises the following steps: step 1, selecting two groups of pregnant SD rats, injecting Poly I: C into tail veins of one group of SD rats after 9.5 days of pregnancy according to the standard of 10 mg / kg, and taking male offspring rats as schizophrenia model group rats; the other group of SD rats are intravenously injected with equal-volume normal saline at the tail after pregnancy 9.5 days, and the male offspring rats are the control group; 2, the model components are divided into two groups, retinoic acid is fed to one group 45 days after birth according to the standard of 3 mg / kg / day, an equal amount of placebo is injected to the other group, and an equal amount of placebo is injected to the control group; step 3, carrying out behavioral detection experiments on the three groups of rats in the step 2; and 4, implanting electrodes into hippocampal CA1 regions of the three groups of rats in the step 2, and recording and analyzing electroencephalogram activities of the three groups of rats. The experimental method provided by the invention proves that the retinoic acid has good application value in preparation of the schizophrenia medicine.